China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon (NYSE: OGN) during the 6th China International Import Expo (CIIE) in Shanghai. The collaboration is centered around Organon’s Remeron (mirtazapine), with Qingyun playing a role in implementing omnichannel marketing strategies for the drug.
Mirtazapine’s Mechanism of Action and VBP Tender Inclusion
Mirtazapine, classified as a tetracyclic antidepressant (TeCA), works by inhibiting central presynaptic alpha-2-adrenergic receptors, thereby increasing the release of serotonin and norepinephrine. In March 2023, the molecule was included in the 8th national volume-based procurement (VBP) tender, where Organon secured a tender spot by offering a significant 60% price reduction.- Flcube.com